MENU
+Compare
HRTS
ETF ticker: NASDAQ
AS OF
Sep 26, 04:58 PM (EDT)
Price
$29.96
Change
-$0.19 (-0.63%)
Net Assets
48.59M

HRTS stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for HRTS with price predictions
Sep 25, 2025

HRTS sees MACD Histogram crosses below signal line

HRTS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 16, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 21 instances where the indicator turned negative. In of the 21 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HRTS moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator moved out of overbought territory. In of the 9 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on September 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HRTS as a result. In of 27 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HRTS broke above its upper Bollinger Band on September 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 22 cases where HRTS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The 10-day moving average for HRTS crossed bullishly above the 50-day moving average on August 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTS advanced for three days, in of 109 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 59 cases where HRTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Unitedhealth Group (NYSE:UNH), AstraZeneca PLC (NASDAQ:AZN), Abbott Laboratories (NYSE:ABT), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Boston Scientific Corp (NYSE:BSX), Gilead Sciences (NASDAQ:GILD), Medtronic plc (NYSE:MDT).

Industry description

The investment seeks to provide long-term growth of capital. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Heart & Health ETF ETF is 84.95B. The market cap for tickers in the group ranges from 3.51M to 640.6B. LLY holds the highest valuation in this group at 640.6B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Heart & Health ETF ETF was 57%. For the same ETF, the average monthly price growth was 163%, and the average quarterly price growth was 173%. MTSR experienced the highest price growth at 46%, while DXCM experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Tema Heart & Health ETF ETF was -9%. For the same stocks of the ETF, the average monthly volume growth was 14% and the average quarterly volume growth was 51%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 71
Price Growth Rating: 49
SMR Rating: 72
Profit Risk Rating: 70
Seasonality Score: -38 (-100 ... +100)
View a ticker or compare two or three
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co